Shengkun Peng

511 total citations · 1 hit paper
18 papers, 359 citations indexed

About

Shengkun Peng is a scholar working on Oncology, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Shengkun Peng has authored 18 papers receiving a total of 359 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Cancer Research and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Shengkun Peng's work include Radiomics and Machine Learning in Medical Imaging (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Shengkun Peng is often cited by papers focused on Radiomics and Machine Learning in Medical Imaging (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Shengkun Peng collaborates with scholars based in China, Taiwan and United States. Shengkun Peng's co-authors include Yaow-Ming Chen, Yu‐Chung Chuang, Peng Luo, Anqi Lin, Zaoqu Liu, Quan Cheng, Aimin Jiang, Yuanxi Peng, Chaozheng Zhou and Jian Zhang and has published in prestigious journals such as Journal of Hepatology, European Journal of Cancer and Frontiers in Oncology.

In The Last Decade

Shengkun Peng

17 papers receiving 355 citations

Hit Papers

Psychiatric disorders associated with immune checkpoint i... 2023 2026 2024 2025 2023 25 50 75 100
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
    2023 114 citations Chaozheng Zhou, Shengkun Peng et al. EClinicalMedicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shengkun Peng China 8 119 110 69 54 41 18 359
Scott R. Silva United States 11 303 2.5× 184 1.7× 162 2.3× 54 1.0× 73 1.8× 28 615
John K. O’Connor United States 7 69 0.6× 84 0.8× 122 1.8× 23 0.4× 53 1.3× 16 409
J. P. Eder United States 10 143 1.2× 148 1.3× 9 0.1× 38 0.7× 77 1.9× 21 418
Teppei Sakamoto Japan 12 204 1.7× 109 1.0× 118 1.7× 18 0.3× 124 3.0× 34 466
Karen Zempolich United States 11 219 1.8× 196 1.8× 113 1.6× 9 0.2× 89 2.2× 18 635
Caroline Archer United Kingdom 11 124 1.0× 244 2.2× 20 0.3× 18 0.3× 99 2.4× 21 522
Carolina Ortiz Spain 9 158 1.3× 218 2.0× 24 0.3× 16 0.3× 88 2.1× 27 433
Julie Iddon United Kingdom 7 156 1.3× 241 2.2× 17 0.2× 17 0.3× 115 2.8× 13 447
Yoshimasa Nobeyama Japan 11 235 2.0× 76 0.7× 75 1.1× 12 0.2× 105 2.6× 53 606
Fernando Cordera Mexico 11 187 1.6× 173 1.6× 42 0.6× 7 0.1× 69 1.7× 28 596

Countries citing papers authored by Shengkun Peng

Since Specialization
Citations

This map shows the geographic impact of Shengkun Peng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengkun Peng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengkun Peng more than expected).

Fields of papers citing papers by Shengkun Peng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengkun Peng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengkun Peng. The network helps show where Shengkun Peng may publish in the future.

Co-authorship network of co-authors of Shengkun Peng

This figure shows the co-authorship network connecting the top 25 collaborators of Shengkun Peng. A scholar is included among the top collaborators of Shengkun Peng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengkun Peng. Shengkun Peng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Hu, Lei, Shan Huang, Xijian Chen, et al.. (2025). Pericoronary Adipose Tissue CT Attenuation in Kawasaki Disease and Association with Coronary Artery Aneurysms, Myocardial Perfusion, and Coronary Events. Radiology Cardiothoracic Imaging. 7(3). e240303–e240303.
2.
Peng, Shengkun, Hongyu Kuang, Anqi Lin, et al.. (2025). From bench to bedside: elucidating VEGF(R) inhibitor-related heart failure in cancer treatment. Journal of Translational Medicine. 23(1). 109–109. 1 indexed citations
3.
Hu, Lei, Shengkun Peng, Yingkun Guo, et al.. (2024). Myocardial perfusion impairment in children with Kawasaki disease: assessment with cardiac magnetic resonance first-pass perfusion. Quantitative Imaging in Medicine and Surgery. 14(7). 4923–4935. 3 indexed citations
4.
Fu, Jing & Shengkun Peng. (2023). Triple-negative mouse breast cancer initiating cells show high expression of beta1 integrin and increased malignant features. Open Life Sciences. 18(1). 20220510–20220510. 1 indexed citations
5.
Zhou, Chaozheng, Shengkun Peng, Anqi Lin, et al.. (2023). Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. EClinicalMedicine. 59. 101967–101967. 114 indexed citations breakdown →
6.
7.
Zhang, Guojin, Jing Zhang, Yuntai Cao, et al.. (2022). Development of a Nomogram Based on 3D CT Radiomics Signature to Predict the Mutation Status of EGFR Molecular Subtypes in Lung Adenocarcinoma: A Multicenter Study. Frontiers in Oncology. 12. 889293–889293. 2 indexed citations
8.
Song, Linsheng, Xinyi Zhao, Jie Zeng, et al.. (2022). Preliminary study on the diagnostic value of cardiac magnetic resonance feature tracking for malignant ventricular arrhythmias in non-ischemic dilated cardiomyopathy. Annals of Translational Medicine. 10(4). 215–215. 7 indexed citations
9.
Yu, Xueqing, et al.. (2022). Detection of idiopathic pulmonary fibrosis lesion regions based on corner point distribution. 2022 7th International Conference on Intelligent Computing and Signal Processing (ICSP). 502–506. 2 indexed citations
10.
Wang, Youyu, Xiaohua Li, Shengkun Peng, et al.. (2021). Single-Cell Analysis Reveals Spatial Heterogeneity of Immune Cells in Lung Adenocarcinoma. Frontiers in Cell and Developmental Biology. 9. 638374–638374. 16 indexed citations
11.
Peng, Shengkun, Lingai Pan, Shaojin Zhang, et al.. (2020). Imaging Features in COVID-19 Patients: Analysis of Data from Patients in Non-Pandemic Areas. SSRN Electronic Journal. 1 indexed citations
12.
Song, Linhong, et al.. (2020). [Comparison of radiological and clinicopathological features of craniofacial fibro-osseous lesions].. PubMed. 49(2). 122–128. 2 indexed citations
13.
Chuang, Yu‐Chung, et al.. (2009). Risk stratification for predicting 30-day mortality of intracerebral hemorrhage. International Journal for Quality in Health Care. 21(6). 441–447. 51 indexed citations
14.
15.
16.
Peng, Shengkun, Y.-H. Ou, Wei J. Chen, et al.. (2005). Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma.. 17 indexed citations
17.
Peng, Shengkun, et al.. (1994). Mutations of P53 Gene in Hepatocellular Carcinoma (HCC) Correlate with Tumor Progression and Patient Prognosis. 1341–1347. 7 indexed citations
18.
Peng, Shengkun, et al.. (1993). Amplification of the c-myc gene in human hepatocellular carcinoma: biologic significance.. PubMed. 92(10). 866–70. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Scott R. Silva Breakdown of academic impact, for papers by John K. O’Connor Breakdown of academic impact, for papers by J. P. Eder Breakdown of academic impact, for papers by Teppei Sakamoto Breakdown of academic impact, for papers by Karen Zempolich Breakdown of academic impact, for papers by Caroline Archer Breakdown of academic impact, for papers by Carolina Ortiz Breakdown of academic impact, for papers by Julie Iddon Breakdown of academic impact, for papers by Yoshimasa Nobeyama Breakdown of academic impact, for papers by Fernando Cordera
Rankless by CCL
2026